| __timestamp | Intra-Cellular Therapies, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 5078000000 |
| Thursday, January 1, 2015 | 18187286 | 4717000000 |
| Friday, January 1, 2016 | 24758063 | 5096000000 |
| Sunday, January 1, 2017 | 23666957 | 4986000000 |
| Monday, January 1, 2018 | 30099855 | 4214000000 |
| Tuesday, January 1, 2019 | 64947625 | 3806000000 |
| Wednesday, January 1, 2020 | 186363444 | 3671000000 |
| Friday, January 1, 2021 | 272611040 | 3528000000 |
| Saturday, January 1, 2022 | 358782000 | 3445000000 |
| Sunday, January 1, 2023 | 409864000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Unlocking the unknown
In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and Intra-Cellular Therapies, Inc. from 2014 to 2023.
Teva, a global leader, has seen a significant reduction in SG&A expenses, dropping from approximately $5 billion in 2014 to $3.5 billion in 2023. This 30% decrease reflects strategic cost management amidst industry challenges. In contrast, Intra-Cellular Therapies, a burgeoning player, experienced a dramatic increase in SG&A expenses, skyrocketing from $10 million in 2014 to $410 million in 2023, a staggering 3,860% rise. This surge underscores their aggressive expansion and investment in innovation.
These contrasting trends highlight the diverse strategies employed by established and emerging pharmaceutical companies in navigating the competitive landscape.
Who Optimizes SG&A Costs Better? Sanofi or Teva Pharmaceutical Industries Limited
Cost Management Insights: SG&A Expenses for Zoetis Inc. and Intra-Cellular Therapies, Inc.
Teva Pharmaceutical Industries Limited and Viatris Inc.: SG&A Spending Patterns Compared
Teva Pharmaceutical Industries Limited and Verona Pharma plc: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs ImmunityBio, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Vericel Corporation
Intra-Cellular Therapies, Inc. vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Alkermes plc
Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Intra-Cellular Therapies, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Intra-Cellular Therapies, Inc. vs Perrigo Company plc: SG&A Expense Trends
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Dynavax Technologies Corporation Trends and Insights